Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial

被引：9

作者：

Gelbenegger, Georg ^{[1
]}

Jaeger, Ulrich ^{[2
]}

Fillitz, Michael ^{[3
]}

D'Sa, Shirley ^{[4
]}

Cartwright, Ronwyn ^{[5
]}

Shafer, Frank ^{[6
]}

Wardecki, Marek ^{[7
]}

Wang, Jennifer ^{[6
]}

Schoergenhofer, Christian ^{[1
]}

Jilma, Bernd ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria

[2] Med Univ Vienna, Div Haematol & Haemostasis, Dept Med 1, Vienna, Austria

[3] Hanusch Hosp, Dept Med, Vienna, Austria

[4] Univ Coll London Hosp UCLH, Natl Hlth Serv NHS Fdn Trust, Ctr Waldenstroms Macroglobulinaemia & Related Con, UCLH, London, England

[5] Worthing Dist Hosp, Western Sussex Hosp, NHS Fdn Trust, Worthing, England

[6] Sanofi, Cambridge, MA USA

[7] Sanofi, Warsaw, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 04期

关键词：

D O I：

10.1111/bjh.18289

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E59 / E62

页数：4

共 50 条

[1] Sutimlimab provides sustained improvements in patient-reported outcomes and quality of life in patients with cold agglutinin disease: open-label extension of the randomized, Phase 3 CADENZA Study
Roth, A.
Broome, C. M.
Barcellini, W.
Jilma, B.
Hill, Q. A.
Cella, D.
Tvedt, T. H. A.
Yamaguchi, M.
Murakhovskaya, I
Lee, M.
Shafer, F.
Wardecki, M.
Wang, J.
Yoo, R.
Msihid, J.
Weitz, I. C.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 297 - 297
[2] Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
Roeth, Alexander
Broome, Catherine M.
Barcellini, Wilma
Jilma, Bernd
Hill, Quentin A.
Cella, David
Tvedt, Tor Henrik Anderson
Yamaguchi, Masaki
Murakhovskaya, Irina
Lee, Michelle
Shafer, Frank
Wardecki, Marek
Wang, Jennifer
Yoo, Ronnie
Mshijid, Jerome
Weitz, Ilene C.
[J]. BLOOD, 2022, 140
[3] Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension
Roeth, Alexander
Broome, Catherine M.
Barcellini, Wilma
Jilma, Bernd
Hill, Quentin A.
Cella, David
Tvedt, Tor Henrik Anderson
Yamaguchi, Masaki
Murakhovskaya, Irina
Lee, Michelle
Shafer, Frank
Wardecki, Marek
Jayawardene, Deepthi
Yoo, Ronnie
Msihid, Jerome
Weitz, Ilene C.
[J]. ECLINICALMEDICINE, 2024, 74
[4] Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
Roeth, Alexander
Bommer, Martin
Huettmann, Andreas
Herich-Terhuerne, Doerte
Kuklik, Nils
Rekowski, Jan
Lenz, Veronika
Schrezenmeier, Hubert
Duehrsen, Ulrich
[J]. BLOOD ADVANCES, 2018, 2 (19) : 2543 - 2549
[5] Sutimlimab in patients with cold agglutinin disease results of the randomized placebo-controlled phase 3 CADENZA trial
Roeth, Alexander
Berentsen, Sigbjorn
Barcellini, Wilma
D'Sa, Shirley
Jilma, Bernd
Michel, Marc
Weitz, Ilene C.
Yamaguchi, Masaki
Nishimura, Jun-ichi
Vos, Josephine M., I
Storek, Michael
Wong, Nancy
Patel, Parija
Jiang, Xiaoyu
Vagge, Deepthi S.
Wardecki, Marek
Shafer, Frank
Lee, Michelle
Broome, Catherine M.
[J]. BLOOD, 2022, 140 (09) : 980 - 991
[6] Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
Gelbenegger, Georg
Jaeger, Ulrich
Fillitz, Michael
Schoergenhofer, Christian
Sillaber, Christian
Jilma, Bernd
[J]. BLOOD ADVANCES, 2023, 7 (10) : 1987 - 1990
[7] Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
Roeth, Alexander
Barcellini, Wilma
D'Sa, Shirley
Miyakawa, Yoshitaka
Broome, Catherine M.
Michel, Marc
Kuter, David J.
Jilma, Bernd
Tvedt, Tor Henrik Anderson
Weitz, Ilene C.
Yoo, Ronnie
Jayawardene, Deepthi
Vagge, Deepthi S.
Kralova, Katarina
Shafer, Frank
Wardecki, Marek
Lee, Michelle
Berentsen, Sigbjorn
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (08) : 1246 - 1253
[8] Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
Doody, RS
Geldmacher, DS
Gordon, B
Perdomo, CA
Pratt, RD
[J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 427 - 433
[9] PHASE 3 TRIAL OF TOLVAPTAN IN PEDIATRIC AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): TWO YEARS OF DATA FROM AN OPEN-LABEL EXTENSION
Mekahli, Djalila
Guay-Woodford, Lisa
Cadnaparphornchai, Melissa
Greenbaum, Laurence A.
Litwin, Mieczyslaw
Seeman, Tomas
Dandurand, Ann
Zhang, Zhen
Sikes, Kimberley
Shoaf, Susan
Schaefer, Franz
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I644 - I646
[10] PHASE 3 TRIAL OF TOLVAPTAN IN PEDIATRIC AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): TWO YEARS OF DATA FROM AN OPEN-LABEL EXTENSION
Mekahli, Djalila
Guay-Woodford, Lisa
Cadnapaphornchai, Melissa
Greenbaum, Larry
Litwin, Mieczyslaw
Seeman, Tomas
Dandurand, Ann
Zhang, Zhen
Sikes, Kimberly
Shoaf, Susan
Schaefer, Franz
[J]. PEDIATRIC NEPHROLOGY, 2023, 38 : S46 - S47

← 1 2 3 4 5 →